WO2000037114B1 - Methods and compositions comprising monitoring devices - Google Patents
Methods and compositions comprising monitoring devicesInfo
- Publication number
- WO2000037114B1 WO2000037114B1 PCT/US1999/030508 US9930508W WO0037114B1 WO 2000037114 B1 WO2000037114 B1 WO 2000037114B1 US 9930508 W US9930508 W US 9930508W WO 0037114 B1 WO0037114 B1 WO 0037114B1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- disorder
- drug
- patient
- mycobacterium
- disease
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract 14
- 239000000203 mixture Substances 0.000 title abstract 3
- 238000012806 monitoring device Methods 0.000 title 1
- 239000003814 drug Substances 0.000 claims abstract 16
- 229940079593 drug Drugs 0.000 claims abstract 16
- 238000001514 detection method Methods 0.000 claims abstract 10
- 238000002651 drug therapy Methods 0.000 claims abstract 5
- 238000012544 monitoring process Methods 0.000 claims abstract 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 9
- 208000015181 infectious disease Diseases 0.000 claims 8
- 208000035475 disorder Diseases 0.000 claims 7
- 208000035473 Communicable disease Diseases 0.000 claims 6
- 239000007850 fluorescent dye Substances 0.000 claims 6
- 241000186359 Mycobacterium Species 0.000 claims 4
- 208000027531 mycobacterial infectious disease Diseases 0.000 claims 4
- 208000020016 psychiatric disease Diseases 0.000 claims 3
- BDBMLMBYCXNVMC-UHFFFAOYSA-O 4-[(2e)-2-[(2e,4e,6z)-7-[1,1-dimethyl-3-(4-sulfobutyl)benzo[e]indol-3-ium-2-yl]hepta-2,4,6-trienylidene]-1,1-dimethylbenzo[e]indol-3-yl]butane-1-sulfonic acid Chemical compound OS(=O)(=O)CCCCN1C2=CC=C3C=CC=CC3=C2C(C)(C)C1=CC=CC=CC=CC1=[N+](CCCCS(O)(=O)=O)C2=CC=C(C=CC=C3)C3=C2C1(C)C BDBMLMBYCXNVMC-UHFFFAOYSA-O 0.000 claims 2
- 208000024172 Cardiovascular disease Diseases 0.000 claims 2
- 208000017701 Endocrine disease Diseases 0.000 claims 2
- 208000018522 Gastrointestinal disease Diseases 0.000 claims 2
- 208000029462 Immunodeficiency disease Diseases 0.000 claims 2
- OJMMVQQUTAEWLP-UHFFFAOYSA-N Lincomycin Natural products CN1CC(CCC)CC1C(=O)NC(C(C)O)C1C(O)C(O)C(O)C(SC)O1 OJMMVQQUTAEWLP-UHFFFAOYSA-N 0.000 claims 2
- 208000019693 Lung disease Diseases 0.000 claims 2
- 241001465754 Metazoa Species 0.000 claims 2
- 208000023178 Musculoskeletal disease Diseases 0.000 claims 2
- 241000187478 Mycobacterium chelonae Species 0.000 claims 2
- 241000186363 Mycobacterium kansasii Species 0.000 claims 2
- 241000186362 Mycobacterium leprae Species 0.000 claims 2
- 241000187479 Mycobacterium tuberculosis Species 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 208000012902 Nervous system disease Diseases 0.000 claims 2
- 239000004098 Tetracycline Substances 0.000 claims 2
- 229940126575 aminoglycoside Drugs 0.000 claims 2
- -1 aminoglycoside Substances 0.000 claims 2
- 230000001430 anti-depressive effect Effects 0.000 claims 2
- 230000000840 anti-viral effect Effects 0.000 claims 2
- 239000000935 antidepressant agent Substances 0.000 claims 2
- 229940005513 antidepressants Drugs 0.000 claims 2
- 239000004599 antimicrobial Substances 0.000 claims 2
- 239000003782 beta lactam antibiotic agent Substances 0.000 claims 2
- 230000003115 biocidal effect Effects 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 229960002227 clindamycin Drugs 0.000 claims 2
- KDLRVYVGXIQJDK-AWPVFWJPSA-N clindamycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 KDLRVYVGXIQJDK-AWPVFWJPSA-N 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 claims 2
- 208000018631 connective tissue disease Diseases 0.000 claims 2
- 208000010643 digestive system disease Diseases 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000030172 endocrine system disease Diseases 0.000 claims 2
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 claims 2
- 229960002143 fluorescein Drugs 0.000 claims 2
- 208000018685 gastrointestinal system disease Diseases 0.000 claims 2
- 239000003102 growth factor Substances 0.000 claims 2
- 229960004657 indocyanine green Drugs 0.000 claims 2
- 229910052500 inorganic mineral Inorganic materials 0.000 claims 2
- OJMMVQQUTAEWLP-KIDUDLJLSA-N lincomycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@@H](C)O)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 OJMMVQQUTAEWLP-KIDUDLJLSA-N 0.000 claims 2
- 229960005287 lincomycin Drugs 0.000 claims 2
- 150000002632 lipids Chemical class 0.000 claims 2
- 208000019423 liver disease Diseases 0.000 claims 2
- 239000003120 macrolide antibiotic agent Substances 0.000 claims 2
- 239000011707 mineral Substances 0.000 claims 2
- 239000002858 neurotransmitter agent Substances 0.000 claims 2
- 229920001184 polypeptide Polymers 0.000 claims 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims 2
- LISFMEBWQUVKPJ-UHFFFAOYSA-N quinolin-2-ol Chemical compound C1=CC=C2NC(=O)C=CC2=C1 LISFMEBWQUVKPJ-UHFFFAOYSA-N 0.000 claims 2
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 claims 2
- 229940043267 rhodamine b Drugs 0.000 claims 2
- 201000009032 substance abuse Diseases 0.000 claims 2
- 231100000736 substance abuse Toxicity 0.000 claims 2
- 208000011117 substance-related disease Diseases 0.000 claims 2
- 229960005404 sulfamethoxazole Drugs 0.000 claims 2
- 229940124530 sulfonamide Drugs 0.000 claims 2
- 150000003456 sulfonamides Chemical class 0.000 claims 2
- JLKIGFTWXXRPMT-UHFFFAOYSA-N sulphamethoxazole Chemical compound O1C(C)=CC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1 JLKIGFTWXXRPMT-UHFFFAOYSA-N 0.000 claims 2
- 229960002180 tetracycline Drugs 0.000 claims 2
- 229930101283 tetracycline Natural products 0.000 claims 2
- 235000019364 tetracycline Nutrition 0.000 claims 2
- 150000003522 tetracyclines Chemical class 0.000 claims 2
- IEDVJHCEMCRBQM-UHFFFAOYSA-N trimethoprim Chemical compound COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 IEDVJHCEMCRBQM-UHFFFAOYSA-N 0.000 claims 2
- 229960001082 trimethoprim Drugs 0.000 claims 2
- 201000008827 tuberculosis Diseases 0.000 claims 2
- 239000011782 vitamin Substances 0.000 claims 2
- 229940088594 vitamin Drugs 0.000 claims 2
- 229930003231 vitamin Natural products 0.000 claims 2
- 235000013343 vitamin Nutrition 0.000 claims 2
- 150000003722 vitamin derivatives Chemical class 0.000 claims 2
- 239000002132 β-lactam antibiotic Substances 0.000 claims 2
- 229940124586 β-lactam antibiotics Drugs 0.000 claims 2
- 230000008054 signal transmission Effects 0.000 claims 1
- 230000037406 food intake Effects 0.000 abstract 2
- 230000007246 mechanism Effects 0.000 abstract 2
- 239000012678 infectious agent Substances 0.000 abstract 1
- 238000011285 therapeutic regimen Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
- A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
- A61K49/0032—Methine dyes, e.g. cyanine dyes
- A61K49/0034—Indocyanine green, i.e. ICG, cardiogreen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/0059—Measuring for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence
- A61B5/0071—Measuring for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence by measuring fluorescence emission
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/48—Other medical applications
- A61B5/4833—Assessment of subject's compliance to treatment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
- A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
- A61K49/0041—Xanthene dyes, used in vivo, e.g. administered to a mice, e.g. rhodamines, rose Bengal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0063—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0063—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres
- A61K49/0069—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the agent being in a particular physical galenical form
- A61K49/0076—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the agent being in a particular physical galenical form dispersion, suspension, e.g. particles in a liquid, colloid, emulsion
- A61K49/0082—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the agent being in a particular physical galenical form dispersion, suspension, e.g. particles in a liquid, colloid, emulsion micelle, e.g. phospholipidic micelle and polymeric micelle
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
- G16H20/10—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H40/00—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices
- G16H40/60—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices
- G16H40/63—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for local operation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/68—Arrangements of detecting, measuring or recording means, e.g. sensors, in relation to patient
- A61B5/6801—Arrangements of detecting, measuring or recording means, e.g. sensors, in relation to patient specially adapted to be attached to or worn on the body surface
- A61B5/6802—Sensor mounted on worn items
- A61B5/681—Wristwatch-type devices
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
- Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medical Informatics (AREA)
- Physics & Mathematics (AREA)
- Surgery (AREA)
- Molecular Biology (AREA)
- Primary Health Care (AREA)
- Heart & Thoracic Surgery (AREA)
- Pathology (AREA)
- Chemical & Material Sciences (AREA)
- Biophysics (AREA)
- General Business, Economics & Management (AREA)
- Business, Economics & Management (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Dispersion Chemistry (AREA)
- Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
- Medical Treatment And Welfare Office Work (AREA)
- Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Testing And Monitoring For Control Systems (AREA)
- Alarm Systems (AREA)
- Selective Calling Equipment (AREA)
- Compositions Of Macromolecular Compounds (AREA)
Abstract
Methods and compositions for the detection and monitoring of drug therapy are provided. In particular, efficient and sensitive methods for the detection of drug ingestion are provided for determining whether individuals are complying with prescribed therapeutic regimens, and for providing a mechanism for identifying drug-resistant strains of infectious agents. The claimed methods and compositions involve the application of transdermal devices containing detection mechanisms for receiving and recording signals generated by the ingestion of a labeled drug. Such devices are attached to the skin for the duration of drug therapy and compliance is determined either by direct reading, or by remote monitoring whereby signals are transmitted from the device and received at an external site such as a healthcare facility.
Claims
1. A method for monitoring drug therapy compliance by a human or animal patient comprising contacting the patient with a transdermal detection device capable of receiving a signal from a labeled drug administered to the patient, wherein transdermal detection of the signal indicates that the patient has received a predetermined amount of the labeled drug.
2. The method of Claim 1, wherein the drug is labeled with a fluorescent label, and the transdermal detection device detects a fluorescent signal emitted from the fluorescent label in the patient.
3. The method of Claim 2, wherein the fluorescent label comprises one or more compounds selected from the group consisting of fluorescein, indocyanin green, and rhodamine B.
4. The method of Claim 1, wherein the labeled drug is a drug selected from the group consisting of an antimicrobial agent, antibiotic, antiviral, antidepressant, β-lactam antibiotic, aminoglycoside, macrolide, lincomycin, clindamycin, tetracycline, quinolone, polypeptide, sulfonamide, trimethoprim, sulfamethoxazole, growth factor, lipid, neurotransmitter, vitamin, and mineral.
5. The method of Claim 1, wherein the drug is administered to treat a disease or disorder selected from the group consisting of infectious disease, immunodeficiency disease, cardiovascular disorder, pulmonary disorder, gastrointestinal disorder, hepatic disorder, biliary disorder, endocrine disorder, cancer, musculoskeletal disorder, connective tissue disorder, neurologic disorder, psychiatric disorder, and genitourinary disorder.
6. The method of Claim 1 , wherein the infectious disease is a mycobacterial disease.
28
7. The method of Claim 6, wherein the mycobacterial disease is caused by infection with a Mycobacterial strain selected from the group consisting of Mycobacterium tuberculosis, Mycobacterium avium-intracellular, Mycobacterium kansasii, Mycobacterium frotiutun, Mycobacterium chelonae, and Mycobacterium leprae.
8. The method of Claim 5, wherein the infectious disease is tuberculosis.
9. The method of Claim 5, wherein the psychiatric disorder is a substance abuse disorder.
10. A device for monitoring drug therapy compliance by a human or animal patient, comprising a transdermal signal detector that transdermally detects the presence of a label of a labeled drug administered to the patient.
11. The device of Claim 10, wherein the detector is in electronic communication with a signal transmission system that transmits detection of the label to a remote signal receiving system.
12. The device of Claim 10, wherein the drug is labeled with a fluorescent label, and the transdermal detection device detects a fluorescent signal emitted from the fluorescent label.
13. The device of Claim 12, wherein the fluorescent label comprises one or more compounds selected from the group consisting of fluorescein, indocyanin green, and rhodamine B.
14. The device of Claim 10, wherein the labeled drug is a drug selected from the group consisting of an antimicrobial agent, antibiotic, antiviral, antidepressant, β-lactam antibiotic, aminoglycoside, macrolide, lincomycin, clindamycin, tetracycline, quinolone, polypeptide, sulfonamide, trimethoprim, sulfamethoxazole, growth factor, lipid, neurotransmitter, vitamin, and mineral.
29
15. The device of Claim 10, wherein the drug is administered to treat a disease or disorder selected from the group consisting of infectious disease, immunodeficiency disease, cardiovascular disorder, pulmonary disorder, gastrointestinal disorder, hepatic disorder, biliary disorder, endocrine disorder, cancer, musculoskeletal disorder, connective tissue disorder, neurologic disorder, psychiatric disorder, and genitourinary disorder.
16. The device of Claim 15, wherein the infectious disease is a mycobacterial disease.
17. The device of Claim 16, wherein the mycobacterial disease is caused by infection with a Mycobacterial strain selected from the group consisting of Mycobacterium tuberculosis, Mycobacterium avium-intracellular, Mycobacterium kansasii, Mycobacterium frotiutun, Mycobacterium chelonae, and Mycobacterium leprae.
18. The device of Claim 15, wherein the infectious disease is tuberculosis.
19. A method for monitoring drug therapy compliance in a patient being treated for substance abuse comprising contacting the patient with a transdermal detection device capable of receiving a signal from a labeled drug administered to the patient, wherein transdermal detection of the signal indicates that the patient has received a predetermined amount of the labeled drug.
Priority Applications (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AT99968162T ATE244022T1 (en) | 1998-12-21 | 1999-12-21 | METHODS OF USE AND COMPOSITIONS CONTAINING MONITORING SYSTEM |
| DE69909327T DE69909327T2 (en) | 1998-12-21 | 1999-12-21 | METHODS OF USE AND COMPILATIONS CONTAINING MONITORING SYSTEM |
| AU24836/00A AU2483600A (en) | 1998-12-21 | 1999-12-21 | Methods and compositions comprising monitoring devices |
| EP99968162A EP1140210B1 (en) | 1998-12-21 | 1999-12-21 | Methods and compositions comprising monitoring devices |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11311698P | 1998-12-21 | 1998-12-21 | |
| US60/113,116 | 1998-12-21 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| WO2000037114A2 WO2000037114A2 (en) | 2000-06-29 |
| WO2000037114A3 WO2000037114A3 (en) | 2000-12-21 |
| WO2000037114B1 true WO2000037114B1 (en) | 2001-04-26 |
| WO2000037114A9 WO2000037114A9 (en) | 2001-07-12 |
Family
ID=22347656
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/US1999/030508 WO2000037114A2 (en) | 1998-12-21 | 1999-12-21 | Methods and compositions comprising monitoring devices |
Country Status (6)
| Country | Link |
|---|---|
| US (3) | US6663846B1 (en) |
| EP (1) | EP1140210B1 (en) |
| AT (1) | ATE244022T1 (en) |
| AU (1) | AU2483600A (en) |
| DE (1) | DE69909327T2 (en) |
| WO (1) | WO2000037114A2 (en) |
Families Citing this family (120)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69909327T2 (en) * | 1998-12-21 | 2004-04-22 | Sequella, Inc. | METHODS OF USE AND COMPILATIONS CONTAINING MONITORING SYSTEM |
| US7062312B2 (en) * | 2001-01-17 | 2006-06-13 | Pediamed Pharmaceuticals, Inc. | Combination and method including a visual marker for determining compliance with a medication regimen |
| US20030194374A1 (en) * | 2001-01-17 | 2003-10-16 | Xanodyne Pharmacal, Inc. | Compositions including a visual marker and method of use thereof |
| US8533029B2 (en) | 2001-04-02 | 2013-09-10 | Invivodata, Inc. | Clinical monitoring device with time shifting capability |
| US7873589B2 (en) | 2001-04-02 | 2011-01-18 | Invivodata, Inc. | Operation and method for prediction and management of the validity of subject reported data |
| US8065180B2 (en) | 2001-04-02 | 2011-11-22 | invivodata®, Inc. | System for clinical trial subject compliance |
| US20050182653A1 (en) * | 2004-02-12 | 2005-08-18 | Joseph Urban | System and method for improving and promoting compliance to a therapeutic regimen |
| US7563891B2 (en) * | 2004-05-21 | 2009-07-21 | Becton, Dickinson & Company | Long wavelength thiol-reactive fluorophores |
| US7712288B2 (en) | 2004-05-28 | 2010-05-11 | Narayanan Ramasubramanian | Unified ingestion package and process for patient compliance with prescribed medication regimen |
| WO2006009910A2 (en) * | 2004-06-17 | 2006-01-26 | The Regents Of The University Of California | Time-resolved optometric fluorescence detection for skin diagnostics |
| US20060062734A1 (en) * | 2004-09-20 | 2006-03-23 | Melker Richard J | Methods and systems for preventing diversion of prescription drugs |
| JP4648698B2 (en) * | 2004-12-28 | 2011-03-09 | ユニ・チャーム株式会社 | Sanitary napkin |
| US8802183B2 (en) | 2005-04-28 | 2014-08-12 | Proteus Digital Health, Inc. | Communication system with enhanced partial power source and method of manufacturing same |
| US8730031B2 (en) | 2005-04-28 | 2014-05-20 | Proteus Digital Health, Inc. | Communication system using an implantable device |
| EP2392258B1 (en) | 2005-04-28 | 2014-10-08 | Proteus Digital Health, Inc. | Pharma-informatics system |
| US8912908B2 (en) | 2005-04-28 | 2014-12-16 | Proteus Digital Health, Inc. | Communication system with remote activation |
| US9198608B2 (en) | 2005-04-28 | 2015-12-01 | Proteus Digital Health, Inc. | Communication system incorporated in a container |
| US8836513B2 (en) | 2006-04-28 | 2014-09-16 | Proteus Digital Health, Inc. | Communication system incorporated in an ingestible product |
| WO2006127355A2 (en) * | 2005-05-20 | 2006-11-30 | Dow Global Technologies Inc. | Oral drug compliance monitoring using radio frequency identification tags |
| AU2006251454A1 (en) * | 2005-05-24 | 2006-11-30 | Responsif Gmbh | Method for producing virus-type particles containing an active substance |
| EP1909765A1 (en) * | 2005-07-22 | 2008-04-16 | Dow Gloval Technologies Inc. | Oral drug compliance monitoring using sound detection |
| WO2007028035A2 (en) | 2005-09-01 | 2007-03-08 | Proteus Biomedical, Inc. | Implantable zero-wire communications system |
| US20070135691A1 (en) * | 2005-12-12 | 2007-06-14 | General Electric Company | Medicament compliance monitoring system, method, and medicament container |
| CN102323984A (en) * | 2006-03-30 | 2012-01-18 | 陶氏环球技术有限责任公司 | Be used to monitor and analyze the method and system of complying with of body innerlich anwenden scheme |
| CA2649447A1 (en) | 2006-04-25 | 2007-11-08 | Dow Global Technologies Inc. | Oral drug compliance monitoring using magnetic-field sensors |
| CN105468895A (en) | 2006-05-02 | 2016-04-06 | 普罗透斯数字保健公司 | Patient customized therapeutic regimens |
| WO2008066617A2 (en) | 2006-10-17 | 2008-06-05 | Proteus Biomedical, Inc. | Low voltage oscillator for medical devices |
| EP2083680B1 (en) | 2006-10-25 | 2016-08-10 | Proteus Digital Health, Inc. | Controlled activation ingestible identifier |
| EP2069004A4 (en) | 2006-11-20 | 2014-07-09 | Proteus Digital Health Inc | Active signal processing personal health signal receivers |
| MY165532A (en) | 2007-02-01 | 2018-04-02 | Proteus Digital Health Inc | Ingestible event marker systems |
| CA2676280C (en) | 2007-02-14 | 2018-05-22 | Proteus Biomedical, Inc. | In-body power source having high surface area electrode |
| US9270025B2 (en) | 2007-03-09 | 2016-02-23 | Proteus Digital Health, Inc. | In-body device having deployable antenna |
| EP2124725A1 (en) | 2007-03-09 | 2009-12-02 | Proteus Biomedical, Inc. | In-body device having a multi-directional transmitter |
| US8540632B2 (en) | 2007-05-24 | 2013-09-24 | Proteus Digital Health, Inc. | Low profile antenna for in body device |
| DK2192946T3 (en) | 2007-09-25 | 2022-11-21 | Otsuka Pharma Co Ltd | In-body device with virtual dipole signal amplification |
| MY161533A (en) | 2008-03-05 | 2017-04-28 | Proteus Digital Health Inc | Multi-mode communication ingestible event markers and systems, and methods of using the same |
| US8252529B2 (en) * | 2008-06-12 | 2012-08-28 | The Invention Science Fund I, Llc | Methods for collecting and detecting oligonucleotides |
| US8252528B2 (en) * | 2008-06-12 | 2012-08-28 | The Invention Science Fund I, Llc | Methods, compositions, and kits for collecting and detecting oligonucleotides |
| US8614057B2 (en) * | 2008-06-12 | 2013-12-24 | The Invention Science Fund I, Llc | Methods for collecting and detecting oligonucleotides |
| SG195535A1 (en) | 2008-07-08 | 2013-12-30 | Proteus Digital Health Inc | Ingestible event marker data framework |
| US8271295B1 (en) | 2008-07-23 | 2012-09-18 | Sprint Communications Company L.P. | Health clinic broker |
| US8380531B2 (en) | 2008-07-25 | 2013-02-19 | Invivodata, Inc. | Clinical trial endpoint development process |
| KR101214453B1 (en) | 2008-08-13 | 2012-12-24 | 프로테우스 디지털 헬스, 인코포레이티드 | Ingestible circuitry |
| US8591454B2 (en) * | 2008-11-10 | 2013-11-26 | The Invention Science Fund I, Llc | Administering a therapeutic agent with more than one taggant |
| US20100121581A1 (en) * | 2008-11-10 | 2010-05-13 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Administering a therapeutic agent with more than one taggant |
| US8394638B2 (en) * | 2008-11-10 | 2013-03-12 | The Invention Science Fund I, Llc | Administering a therapeutic agent with more than one taggant |
| US20100121176A1 (en) * | 2008-11-10 | 2010-05-13 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Administering a therapeutic agent with more than one taggant |
| US20100121177A1 (en) * | 2008-11-10 | 2010-05-13 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Administering a therapeutic agent with more than one taggant |
| US8535261B2 (en) * | 2008-11-10 | 2013-09-17 | The Invention Science Fund I, Llc | Administering a therapeutic agent with more than one taggant |
| US20100119455A1 (en) * | 2008-11-10 | 2010-05-13 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Administering a therapeutic agent with more than one taggant |
| US20100121187A1 (en) * | 2008-11-10 | 2010-05-13 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Administering a therapeutic agent with more than one taggant |
| WO2010057049A2 (en) | 2008-11-13 | 2010-05-20 | Proteus Biomedical, Inc. | Ingestible therapy activator system and method |
| CN102271578B (en) | 2008-12-11 | 2013-12-04 | 普罗秋斯数字健康公司 | Evaluation of gastrointestinal function using portable electroviscerography systems and methods of using the same |
| TWI424832B (en) | 2008-12-15 | 2014-02-01 | Proteus Digital Health Inc | Body-associated receiver and method |
| US9439566B2 (en) | 2008-12-15 | 2016-09-13 | Proteus Digital Health, Inc. | Re-wearable wireless device |
| US9659423B2 (en) | 2008-12-15 | 2017-05-23 | Proteus Digital Health, Inc. | Personal authentication apparatus system and method |
| TWI602561B (en) | 2009-01-06 | 2017-10-21 | 波提亞斯數位康健公司 | Pharmaceutical dosages delivery system |
| AU2010203625A1 (en) | 2009-01-06 | 2011-07-21 | Proteus Digital Health, Inc. | Ingestion-related biofeedback and personalized medical therapy method and system |
| US8224667B1 (en) * | 2009-02-06 | 2012-07-17 | Sprint Communications Company L.P. | Therapy adherence methods and architecture |
| WO2010111403A2 (en) | 2009-03-25 | 2010-09-30 | Proteus Biomedical, Inc. | Probablistic pharmacokinetic and pharmacodynamic modeling |
| CN102458236B (en) | 2009-04-28 | 2016-01-27 | 普罗秋斯数字健康公司 | The Ingestible event marker of high reliability and using method thereof |
| WO2010132331A2 (en) | 2009-05-12 | 2010-11-18 | Proteus Biomedical, Inc. | Ingestible event markers comprising an ingestible component |
| US8558563B2 (en) | 2009-08-21 | 2013-10-15 | Proteus Digital Health, Inc. | Apparatus and method for measuring biochemical parameters |
| TWI517050B (en) | 2009-11-04 | 2016-01-11 | 普羅托斯數位健康公司 | System for supply chain management |
| UA109424C2 (en) | 2009-12-02 | 2015-08-25 | PHARMACEUTICAL PRODUCT, PHARMACEUTICAL TABLE WITH ELECTRONIC MARKER AND METHOD OF MANUFACTURING PHARMACEUTICAL TABLETS | |
| JP5841951B2 (en) | 2010-02-01 | 2016-01-13 | プロテウス デジタル ヘルス， インコーポレイテッド | Data collection system |
| WO2011127252A2 (en) | 2010-04-07 | 2011-10-13 | Proteus Biomedical, Inc. | Miniature ingestible device |
| TWI557672B (en) | 2010-05-19 | 2016-11-11 | 波提亞斯數位康健公司 | Computer system and computer-implemented method to track medication from manufacturer to a patient, apparatus and method for confirming delivery of medication to a patient, patient interface device |
| CN103038818B (en) | 2010-06-24 | 2016-10-12 | 本田技研工业株式会社 | Communication system between the outer speech recognition system of vehicle-mounted voice identification system and car and method |
| JP2014504902A (en) | 2010-11-22 | 2014-02-27 | プロテウス デジタル ヘルス， インコーポレイテッド | Ingestible device with medicinal product |
| US9439599B2 (en) | 2011-03-11 | 2016-09-13 | Proteus Digital Health, Inc. | Wearable personal body associated device with various physical configurations |
| US10445846B2 (en) | 2011-04-14 | 2019-10-15 | Elwha Llc | Cost-effective resource apportionment technologies suitable for facilitating therapies |
| US9626650B2 (en) | 2011-04-14 | 2017-04-18 | Elwha Llc | Cost-effective resource apportionment technologies suitable for facilitating therapies |
| US9756874B2 (en) | 2011-07-11 | 2017-09-12 | Proteus Digital Health, Inc. | Masticable ingestible product and communication system therefor |
| WO2015112603A1 (en) | 2014-01-21 | 2015-07-30 | Proteus Digital Health, Inc. | Masticable ingestible product and communication system therefor |
| BR112014001397A2 (en) | 2011-07-21 | 2017-02-21 | Proteus Biomedical Inc | device, system and method of mobile communication |
| US8816814B2 (en) | 2011-08-16 | 2014-08-26 | Elwha Llc | Systematic distillation of status data responsive to whether or not a wireless signal has been received and relating to regimen compliance |
| US9235683B2 (en) | 2011-11-09 | 2016-01-12 | Proteus Digital Health, Inc. | Apparatus, system, and method for managing adherence to a regimen |
| US10276054B2 (en) | 2011-11-29 | 2019-04-30 | Eresearchtechnology, Inc. | Methods and systems for data analysis |
| WO2014018454A1 (en) | 2012-07-23 | 2014-01-30 | Proteus Digital Health, Inc. | Techniques for manufacturing ingestible event markers comprising an ingestible component |
| JP5869736B2 (en) | 2012-10-18 | 2016-02-24 | プロテウス デジタル ヘルス， インコーポレイテッド | Apparatus, system, and method for adaptively optimizing power dissipation and broadcast power in a power supply for a communication device |
| TWI659994B (en) | 2013-01-29 | 2019-05-21 | 美商普羅托斯數位健康公司 | Highly-swellable polymeric films and compositions comprising the same |
| WO2014151929A1 (en) | 2013-03-15 | 2014-09-25 | Proteus Digital Health, Inc. | Personal authentication apparatus system and method |
| JP5941240B2 (en) | 2013-03-15 | 2016-06-29 | プロテウス デジタル ヘルス， インコーポレイテッド | Metal detector device, system and method |
| US9665689B2 (en) | 2013-05-17 | 2017-05-30 | Viavi Solutions Inc. | Medication assurance system and method |
| JP6511439B2 (en) | 2013-06-04 | 2019-05-15 | プロテウス デジタル ヘルス， インコーポレイテッド | Systems, devices, and methods for data collection and outcome assessment |
| US9796576B2 (en) | 2013-08-30 | 2017-10-24 | Proteus Digital Health, Inc. | Container with electronically controlled interlock |
| AU2014321320B2 (en) | 2013-09-20 | 2019-03-14 | Otsuka Pharmaceutical Co., Ltd. | Methods, devices and systems for receiving and decoding a signal in the presence of noise using slices and warping |
| WO2015044722A1 (en) | 2013-09-24 | 2015-04-02 | Proteus Digital Health, Inc. | Method and apparatus for use with received electromagnetic signal at a frequency not known exactly in advance |
| US10084880B2 (en) | 2013-11-04 | 2018-09-25 | Proteus Digital Health, Inc. | Social media networking based on physiologic information |
| US11051543B2 (en) | 2015-07-21 | 2021-07-06 | Otsuka Pharmaceutical Co. Ltd. | Alginate on adhesive bilayer laminate film |
| US10545048B2 (en) | 2015-07-23 | 2020-01-28 | Cardinal Health Commercial Technologies, Llc | Medication dispensing device and methods |
| US9928230B1 (en) | 2016-09-29 | 2018-03-27 | Vignet Incorporated | Variable and dynamic adjustments to electronic forms |
| US9858063B2 (en) | 2016-02-10 | 2018-01-02 | Vignet Incorporated | Publishing customized application modules |
| KR20210018961A (en) | 2016-07-22 | 2021-02-18 | 프로테우스 디지털 헬스, 인코포레이티드 | Electromagnetic sensing and detection of ingestible event markers |
| IL265827B2 (en) | 2016-10-26 | 2023-03-01 | Proteus Digital Health Inc | Methods for manufacturing capsules with ingestible event markers |
| AU2017201991B1 (en) * | 2017-03-24 | 2018-06-21 | Othman Abdul Rahim Radi Al Hanbali | System and method for drug dosage medicament regime adherence monitoring |
| US20200148231A1 (en) * | 2017-06-16 | 2020-05-14 | Ford Global Technologies, Llc | Vehicle occupant impairment detection |
| US11013436B2 (en) | 2017-09-06 | 2021-05-25 | Medtronic, Inc. | Marker monitoring via a medical device |
| US10775974B2 (en) | 2018-08-10 | 2020-09-15 | Vignet Incorporated | User responsive dynamic architecture |
| US11607119B2 (en) * | 2018-12-17 | 2023-03-21 | Qatar University | Fluorescence lifetime spectroscopy based capsule endoscopy |
| US11399807B2 (en) * | 2019-11-05 | 2022-08-02 | International Business Machines Corporation | Non-invasive detection of ingested medications |
| US11328796B1 (en) | 2020-02-25 | 2022-05-10 | Vignet Incorporated | Techniques for selecting cohorts for decentralized clinical trials for pharmaceutical research |
| US11605038B1 (en) | 2020-05-18 | 2023-03-14 | Vignet Incorporated | Selecting digital health technology to achieve data collection compliance in clinical trials |
| US11461216B1 (en) | 2020-05-18 | 2022-10-04 | Vignet Incorporated | Monitoring and improving data collection using digital health technology |
| US11763919B1 (en) | 2020-10-13 | 2023-09-19 | Vignet Incorporated | Platform to increase patient engagement in clinical trials through surveys presented on mobile devices |
| US11417418B1 (en) | 2021-01-11 | 2022-08-16 | Vignet Incorporated | Recruiting for clinical trial cohorts to achieve high participant compliance and retention |
| US20240042430A1 (en) * | 2021-01-22 | 2024-02-08 | Drizzle Health Llc | Apparatus and methods for selective capture of mycobacteria |
| US11240329B1 (en) | 2021-01-29 | 2022-02-01 | Vignet Incorporated | Personalizing selection of digital programs for patients in decentralized clinical trials and other health research |
| US11316941B1 (en) | 2021-02-03 | 2022-04-26 | Vignet Incorporated | Remotely managing and adapting monitoring programs using machine learning predictions |
| US11281553B1 (en) | 2021-04-16 | 2022-03-22 | Vignet Incorporated | Digital systems for enrolling participants in health research and decentralized clinical trials |
| US11789837B1 (en) | 2021-02-03 | 2023-10-17 | Vignet Incorporated | Adaptive data collection in clinical trials to increase the likelihood of on-time completion of a trial |
| US11586524B1 (en) | 2021-04-16 | 2023-02-21 | Vignet Incorporated | Assisting researchers to identify opportunities for new sub-studies in digital health research and decentralized clinical trials |
| US11196656B1 (en) | 2021-02-03 | 2021-12-07 | Vignet Incorporated | Improving diversity in cohorts for health research |
| US11521714B1 (en) | 2021-02-03 | 2022-12-06 | Vignet Incorporated | Increasing diversity of participants in health research using adaptive methods |
| US11361846B1 (en) | 2021-02-03 | 2022-06-14 | Vignet Incorporated | Systems and methods for customizing monitoring programs involving remote devices |
| US11296971B1 (en) | 2021-02-03 | 2022-04-05 | Vignet Incorporated | Managing and adapting monitoring programs |
| US11636500B1 (en) | 2021-04-07 | 2023-04-25 | Vignet Incorporated | Adaptive server architecture for controlling allocation of programs among networked devices |
| US11901083B1 (en) | 2021-11-30 | 2024-02-13 | Vignet Incorporated | Using genetic and phenotypic data sets for drug discovery clinical trials |
| US11705230B1 (en) | 2021-11-30 | 2023-07-18 | Vignet Incorporated | Assessing health risks using genetic, epigenetic, and phenotypic data sources |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3806592A (en) * | 1970-12-18 | 1974-04-23 | Rohm & Haas | Method for evaluating bile sufficiency |
| EP0014515B2 (en) | 1979-02-01 | 1991-03-13 | Dentsply International, Inc. | Hardenable compositions, process to make a shaped article therefrom and dental appliance comprising it |
| US4329999A (en) * | 1980-03-03 | 1982-05-18 | Michael Phillips | Patient attached patch and method of making |
| US4732153A (en) * | 1984-07-18 | 1988-03-22 | Michael Phillips | Transdermal dosimeter |
| US5628310A (en) | 1995-05-19 | 1997-05-13 | Joseph R. Lakowicz | Method and apparatus to perform trans-cutaneous analyte monitoring |
| JPH10253622A (en) * | 1997-03-14 | 1998-09-25 | Nippon Schering Kk | Method of measuring state of activity (energy) of cell (tissue) |
| CA2259898A1 (en) * | 1997-05-27 | 1998-12-03 | Boehringer Mannheim Corporation | Conjugates and specific immunoassays for the methadone metabolite 2-ethylidine-1,5-dimethyl-3,3-diphenylpyrrolidine |
| US6068981A (en) * | 1997-10-03 | 2000-05-30 | Biocode, Inc. | Marking of orally ingested products |
| DE69909327T2 (en) * | 1998-12-21 | 2004-04-22 | Sequella, Inc. | METHODS OF USE AND COMPILATIONS CONTAINING MONITORING SYSTEM |
-
1999
- 1999-12-21 DE DE69909327T patent/DE69909327T2/en not_active Expired - Lifetime
- 1999-12-21 WO PCT/US1999/030508 patent/WO2000037114A2/en active IP Right Grant
- 1999-12-21 US US09/468,718 patent/US6663846B1/en not_active Expired - Lifetime
- 1999-12-21 AT AT99968162T patent/ATE244022T1/en not_active IP Right Cessation
- 1999-12-21 AU AU24836/00A patent/AU2483600A/en not_active Abandoned
- 1999-12-21 EP EP99968162A patent/EP1140210B1/en not_active Expired - Lifetime
-
2002
- 2002-04-05 US US10/117,262 patent/US20030165428A1/en not_active Abandoned
-
2004
- 2004-07-07 US US10/886,388 patent/US20050031536A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2000037114A3 (en) | 2000-12-21 |
| DE69909327D1 (en) | 2003-08-07 |
| EP1140210B1 (en) | 2003-07-02 |
| US20050031536A1 (en) | 2005-02-10 |
| EP1140210A2 (en) | 2001-10-10 |
| WO2000037114A2 (en) | 2000-06-29 |
| AU2483600A (en) | 2000-07-12 |
| US20030165428A1 (en) | 2003-09-04 |
| ATE244022T1 (en) | 2003-07-15 |
| US6663846B1 (en) | 2003-12-16 |
| WO2000037114A9 (en) | 2001-07-12 |
| DE69909327T2 (en) | 2004-04-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2000037114B1 (en) | Methods and compositions comprising monitoring devices | |
| Barradell et al. | Artesunate: a review of its pharmacology and therapeutic efficacy in the treatment of malaria | |
| Njenga et al. | Adult population as potential reservoir of NTD infections in rural villages of Kwale district, Coastal Kenya: implications for preventive chemotherapy interventions policy | |
| WO2001006699A3 (en) | System and methods for maintaining and distributing personal security devices | |
| EP1372314A3 (en) | Presence and notification system for maintaining and communicating information | |
| BR9909953A (en) | Method and device in a wireless communication system to divide the functionality of a browser between a wireless client and part of the infrastructure | |
| FR2746565B1 (en) | DEVICE FOR RECEIVING SIGNALS FROM AN IMPLANTED ACTIVE MEDICAL APPARATUS | |
| DE69840510D1 (en) | MEDICAL COMPOSITIONS WITH CHOLESTEROL EFFLUENT EFFECT | |
| HK1030167A1 (en) | Benzopyran and benzothiopyran derivatives having retinoid antagonist like activity. | |
| WO2002086542A8 (en) | A method and apparatus for identifying buried objects using ground penetrating radar | |
| Jensen et al. | The negligible systemic availability of retinoids with multiple and excessive topical application of isotretinoin 0.05% gel (Isotrex) in patients with acne vulgaris | |
| IT1285398B1 (en) | DEVICE AND PROCEDURE FOR TRANSDERMAL ADMINISTRATION BY ELECTROTRANSPORTATION OF FENTANIL AND SUFENTANIL. | |
| Nagai et al. | Growth-inhibitory effects of artesunate, pyrimethamine, and pamaquine against Babesia equi and Babesia caballi in in vitro cultures | |
| AUPN991796A0 (en) | Early detection of lysosomal storage disorders | |
| Reyns et al. | Tissue depletion of amoxicillin and its major metabolites in pigs: influence of the administration route and the simultaneous dosage of clavulanic acid | |
| WO2003083628A3 (en) | System and method for controlling device-to-device accesses within a computer system | |
| Tokumura et al. | Preparation of amoxicillin intragastric buoyant sustained-release tablets and the dissolution characteristics | |
| AU2568200A (en) | Apparatus for determining when a patient is susceptible to defibrillation | |
| Ericzon et al. | Role of bile and bile salts on cyclosporine absorption in dogs | |
| Joseph et al. | Radiotherapy in aggressive cutaneous pseudolymphoma: a case report and review of literature | |
| MA26788A1 (en) | PHARMACEUTICAL COMPOSITIONS FOR ORAL ADMINISTRATION OF PHLOROGLUCINOL AND THEIR PREPARATION | |
| Hawken et al. | Is cough alone adequate to screen HIV-positive persons for tuberculosis preventive therapy in developing countries? | |
| ES2169980B1 (en) | MICROCAPSULES FOR THE PROLONGED RELEASE OF PHARMACOS. | |
| Nathan et al. | Inspection time: a neuropsychophysiological test for measuring the functional integrity of the cholinergic system | |
| Tait et al. | A field trial of azithromycin in the treatment of donovanosis in central Australia: a step towards eradication? |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
| AK | Designated states |
Kind code of ref document: A3 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
| AK | Designated states |
Kind code of ref document: B1 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW |
|
| AL | Designated countries for regional patents |
Kind code of ref document: B1 Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
| B | Later publication of amended claims | ||
| AK | Designated states |
Kind code of ref document: C2 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW |
|
| AL | Designated countries for regional patents |
Kind code of ref document: C2 Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
| COP | Corrected version of pamphlet |
Free format text: PAGES 1/28-28/28, DRAWINGS, REPLACED BY NEW PAGES 1/28-28/28; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 1999968162 Country of ref document: EP |
|
| WWP | Wipo information: published in national office |
Ref document number: 1999968162 Country of ref document: EP |
|
| REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
| WWG | Wipo information: grant in national office |
Ref document number: 1999968162 Country of ref document: EP |